Long-Acting Beta-Agonists (LABAs): New Safe Use Requirements

FDA requires risk management plan and class-labeling changes for all LABAs.

Related Posts:

1. Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp: Drug Safety Communication
2. Benicar (olmesartan): Ongoing Safety Review
3. ADA on Zinc in Denture Cream
4. Rotarix Vaccine: Update to Clinicians and Public Health Professionals
5. Oral Bisphosphonates: Ongoing Safety Review of Atypical Subtrochanteric Femur Fractures